Eurofarma’s $161 Million Acquisition of Hypera Pharma Product Portfolio


Tauil & Chequer (Mayer Brown), Mayer Brown and Cescon, Barrieu, Flesch & Barreto advised on the transaction

Hypera SA signed a deal with Eurofarma Laboratorios SA for the sale of a portfolio of 12 products in Argentina, Colombia, Ecuador, Mexico, Panama and Peru for $161 million.

Eurofarma Laboratorios S.A. manufactures and markets pharmaceutical products. The Company offers drugs exempt from medical prescription, prescription drugs, veterinary drugs, and speciality drugs. Eurofarma Laboratorios serves customer worldwide.

Hypera S.A. operates as a pharmaceutical company. The Company, led by Breno Toledo Pires De Oliveira, Adalmario Ghovatto Satheler Do Couto and Vivian Karina Trujillo Angiolucci, in 2019 recoreded $593 million revenues.

In Brazil, Tauil & Chequer Advogados (Mayer Brown) advised Eurofarma Laboratórios S.A. with Paulo Rage (Picture) and Barbara Leite.

In Mexico, Mayer Brown advised Eurofarma Laboratórios S.A. with Raúl Fernández-Briseño and Francisco Güémez.

Cescon, Barrieu, Flesch & Barreto advised Hypera S.A. with Marcos Rafael Flesch, Ana Carolina Castro Reis Passos, Isabel Neves de Trigueros, Fernando Pinto Xavier Filho and Rodolpho Clemente.

Involved fees earner: Ana Carolina Castro Reis Passos – Cescon, Barrieu, Flesch & Barreto; Marcos Rafael Flesch – Cescon, Barrieu, Flesch & Barreto; Isabel Neves de Trigueros – Cescon, Barrieu, Flesch & Barreto; Fernando Pinto Xavier Filho – Cescon, Barrieu, Flesch & Barreto; Bárbara Eiroa Leite – Mayer Brown; Raúl Fernández-Briseño – Mayer Brown; Paulo Rage – Mayer Brown;

Law Firms: Cescon, Barrieu, Flesch & Barreto; Mayer Brown;

Clients: Eurofarma Laboratórios S.A.; Hypera S.A. ;

Author: Ambrogio Visconti.